Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
DREAM Trial Investigators; Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S. DREAM Trial Investigators, et al. Diabetes Care. 2008 May;31(5):1007-14. doi: 10.2337/dc07-1868. Epub 2008 Feb 11. Diabetes Care. 2008. PMID: 18268075 Free article. Clinical Trial.
Type 2 diabetes mellitus management in Canada: is it improving?
Leiter LA, Berard L, Bowering CK, Cheng AY, Dawson KG, Ekoé JM, Fournier C, Goldin L, Harris SB, Lin P, Ransom T, Tan M, Teoh H, Tsuyuki RT, Whitham D, Woo V, Yale JF, Langer A. Leiter LA, et al. Among authors: woo v. Can J Diabetes. 2013 Apr;37(2):82-9. doi: 10.1016/j.jcjd.2013.02.055. Epub 2013 Apr 23. Can J Diabetes. 2013. PMID: 24070797
Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.
Giugliano D, Tracz M, Shah S, Calle-Pascual A, Mistodie C, Duarte R, Sari R, Woo V, Jiletcovici AO, Deinhard J, Wille SA, Kiljanski J. Giugliano D, et al. Among authors: woo v. Diabetes Care. 2014 Feb;37(2):372-80. doi: 10.2337/dc12-2704. Epub 2013 Oct 29. Diabetes Care. 2014. PMID: 24170763 Clinical Trial.
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. Gough SC, et al. Among authors: woo v. Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1. Lancet Diabetes Endocrinol. 2014. PMID: 25190523 Clinical Trial.
Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
Berard L, Cameron B, Woo V, Stewart J. Berard L, et al. Among authors: woo v. Can J Diabetes. 2015 Aug;39(4):296-301. doi: 10.1016/j.jcjd.2014.12.008. Epub 2015 Mar 24. Can J Diabetes. 2015. PMID: 25819531 Clinical Trial.
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB. Gough SC, et al. Among authors: woo vc. Diabetes Obes Metab. 2015 Oct;17(10):965-73. doi: 10.1111/dom.12498. Epub 2015 Jul 1. Diabetes Obes Metab. 2015. PMID: 25980900 Free PMC article. Clinical Trial.
263 results